ARFORMETEROL;
AZD 3199;
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
BI 1744 CL;
CARMOTEROL;
GSK 159802;
GW 642444;
INDACATEROL;
LAS 100977;
LONG ACTING DRUG;
MILVETEROL;
PF 610355;
SALBUTAMOL;
SALMETEROL;
THIAZOLE DERIVATIVE;
UNCLASSIFIED DRUG;
WO 2008096112;
WO 2008096119;
WO 2008104790;
ASTHMA;
BIOASSAY;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CLINICAL TRIAL;
DRUG CONFORMATION;
DRUG EFFICACY;
DRUG POTENCY;
DRUG RECEPTOR BINDING;
GUINEA PIG;
HUMAN;
IC 50;
IN VITRO STUDY;
NONHUMAN;
PHARMACOPHORE;
REVIEW;
STRUCTURE ANALYSIS;
ADRENERGIC BETA-2 RECEPTOR AGONISTS;
ADRENERGIC BETA-AGONISTS;
ANIMALS;
BENZOTHIAZOLES;
BRONCHODILATOR AGENTS;
CLINICAL TRIALS, PHASE II AS TOPIC;
HUMANS;
PATENTS AS TOPIC;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
Pharmacological similarities and differences between beta2-agonists
•Good discussion of the pharmacodyanmic differences between the marketed beta agonists
Lotvall J. Pharmacological similarities and differences between beta2-agonists. Respir Med 2001;95(Suppl B):S7-11 •Good discussion of the pharmacodyanmic differences between the marketed beta agonists.
Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor
•Comprehenssive elucidation of the molecualr mechanism of the long duration of action of salmeterol
Green SA, Spasoff AP, Coleman RA, et al. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996;271:24029-24035 •Comprehenssive elucidation of the molecualr mechanism of the long duration of action of salmeterol.
Kikkawa H, Isogaya M, Nagao T, Kurose H. The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. Mol Pharmacol 1998;53:128-134 •Description of how carmaterol behaves as a long acting beta 2 agonist. (Pubitemid 28068380)
Astrazeneca AB. Novel Benzothiazolone Derivatives. WO2007018461; 2007
(2007)
8
0037256056
Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: Chronic obstructive pulmonary disease and drug development implications
Calverley P, Keating ET, Goldman M, Casty F. Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications. Respir Med 2003;97(Suppl A):S71-4
